Acceleron Pharma Announces Pricing Of Public Offering Of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that it has priced an underwritten public offering of 3,750,000 shares of common stock at a price to the public of $40.00 per share for gross proceeds of $150 million. In connection with this offering, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock.